查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2103242

生物銀行市場：全球市場預測，2026-2032年

Biobanking Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生物銀行市場將成長至 1,572.4 億美元，複合年成長率為 10.85%。

主要市場統計數據
基準年 2025 764.3億美元
預計年份：2026年 845.1億美元
預測年份 2032 1572.4億美元
複合年成長率 (%) 10.85%

生物銀行執行摘要

生物銀行已成為現代生物醫學研究、精準醫療、藥物研發、基因組學、再生醫學和公共衛生緊急準備的基礎基礎設施。透過收集、處理、儲存、註釋和分發血液、組織、DNA、RNA、細胞、血漿、血清和微生物組等生物檢體，生物樣本庫使研究人員和臨床醫生能夠將生物檢體與高品質的臨床、人口統計、生活方式和分子數據關聯起來。該領域日益受到倫理知情同意模式、互通性標準、低溫運輸可靠性、自動化儲存系統以及符合公認的生物樣本和檢查室品管規範的安全資料管治的影響。需求與人群基因組學計畫、腫瘤學研究、罕見疾病研究、縱向隊列研究、感染疾病監測和生物標記檢驗的擴展密切相關。隨著生物銀行從單純的檢體儲存轉向整合生物檢體訊息，相關人員將檢體完整性、可追溯性、合規性、捐贈者信任和數據品質放在首位。如今，最佳生物銀行策略結合了標準化的預分析工作流程、數位化庫存管理、統一的元資料、品管系統和隱私保護的數據訪問，以支持可重複的科學研究和具有臨床意義的發現。

生物銀行格局的變革性變化

在生物銀行領域，結構性變革正在發生，從以樣本庫為中心的營運模式轉向以資料豐富、網路化和品質為導向的平台。傳統的基於冷凍庫的檢體正透過實驗室自動化、機器人檢體提取、低溫監控、條碼和RFID追蹤、基於雲端的實驗室資訊管理系統以及旨在減少生物檢體處理差異的標準化操作流程而發生轉變。監管和倫理方面的期望也在發生變化，人們越來越關注知情同意、動態同意、檢體再利用、資料匿名化或假名化、跨境轉移以及公平的利益共享。研究計畫越來越需要將生物檢體與縱向臨床記錄、影像資料、多體學資料集、治療反應和真實世界資料關聯起來，這使得元資料完整性與檢體可用性同等重要。另一個重大變化是去中心化和聯合生物樣本庫網路的興起，這些網路能夠在研究生態系統中實現標準化搜尋和管理訪問，同時允許各個機構繼續承擔檢體存儲的責任。此外，永續性對於低溫儲存和液態氮系統至關重要，因為它們需要強大的能源管理、備用方案、災害復原機制和環境課責。這些變化正使生物銀行從被動的支持功能轉變為轉化研究的策略驅動力。

人工智慧對生物銀行的累積影響

人工智慧 (AI) 正在透過改進檢體發現、品管、數據協調、隊列識別和營運效率來變革生物銀行。 AI 工具可以自動註釋臨床和分子資料集，識別元資料中的不一致之處，根據儲存和處理條件預測檢體劣化風險，並最佳化冷凍庫利用率和檢體檢索流程。在研究領域，機器學習增強了將生物檢體與表現型、基因型、影像學特徵和治療結果關聯起來的能力，從而加速生物標記的發現和患者分層。自然語言處理可以從臨床記錄和病理報告中提取結構化變量，在適當的管治下，提高歷史生物檢體庫的效用。 AI 還透過實現隱私保護分析來增強聯邦研究模型，從而允許從分散式資料集中獲得洞見，而無需不必要地移動敏感資訊。然而，AI 的累積影響取決於資料來源、代表性隊列、透明的演算法、可審計性、網路安全以及對隱私和研究倫理要求的遵守情況。投資於精心整理的元資料、標準化的術語表、基於同意的存取控制和人工智慧管治的生物樣本庫，將更有能力支持可重複、負責任和高價值的生物醫學研究。

生物銀行的關鍵區域見解

在亞太地區，受大規模隊列研究、基因組醫學舉措、感染疾病研究網路和傳染病控制項目的推動，中國、印度、日本、韓國、澳大利亞和東南亞等地對標準化生物檢體的需求正在迅速成長。該地區人口的多樣性在基因組學、藥物藥物基因體學和疾病風險研究方面具有很高的科學價值，同時也增加了對統一知情同意、樣本出口管制、數據本地化和品質保證的需求。歐洲擁有結構最完善的生物銀行之一，這得益於跨境研究合作、嚴格的資料保護法規、完善的品管框架以及支援檢體協調、負責任取得和再利用的泛歐研究基礎設施。北美擁有高度發展的生物銀行環境，這得益於成熟的學術醫療中心、人群健康隊列、臨床試驗網路、先進的分子診斷技術和完善的人體研究保護框架。在美國和加拿大，機構審查、隱私合規、互通性和生物樣本品質標準都備受重視。在拉丁美洲，生物銀行能力建構正透過癌症登記、感染疾病研究、婦幼健康研究和基因組多樣性計畫逐步推進，其中巴西和墨西哥在發展區域研究基礎設施方面發揮關鍵作用。非洲因其遺傳多樣性、感染疾病研究需求以及公共衛生領域合作的不斷擴大，正日益成為重要的戰略夥伴。然而，永續資金籌措、低溫運輸韌性、檢查室認證和公平管治仍然是生物樣本庫長期發展的關鍵優先事項。在中東，隨著對國家基因組學計畫、遺傳疾病研究和醫療衛生現代化的投資，生物銀行正與精準醫療策略、人群特定風險評估和罕見疾病研究日益緊密地聯繫在一起。

關鍵群體見解影響生物銀行優先事項

北約成員國透過衛生安全、生物防禦調查、感染疾病防範和建構具有韌性的生物醫學基礎設施參與生物銀行建設，並透過安全的數據交換、檢體可追溯性和機構間協作，支持對新出現的健康威脅做出協調一致的應對。七國集團（G7）國家在科研生物樣本庫、臨床試驗生物檢體管理、國家隊列研究、腫瘤生物生物銀行和基於標準的品管系統方面普遍展現出強大的能力，並在建立符合倫理、可互操作且可重複的生物銀行最佳互通性發揮著重要作用。金磚國家（BRICS）由於其龐大且多元化的人口、不斷擴展的生物醫學研究能力、公共衛生優先事項以及基因組學的日益普及，在生物銀行樣本庫建設中扮演著至關重要的角色，儘管各成員國的監管成熟度、數據管治和基礎設施一致性存在差異。歐盟（EU）擁有最先進的生物銀行管治環境之一，而資料保護、跨國合作、研究倫理和基礎設施協調是生物檢體取得和再利用的核心。東協的生物銀行活動得益於區域內對提升臨床研究能力、感染疾病監測、癌症研究和基因組醫學的共同需求，但也需要協調知情同意流程、生物檢體運輸、檢查室品質和資料保護要求。海灣合作理事會（GCC）成員國正透過國家衛生轉型議程、人群基因組學、罕見疾病研究以及對精準醫療基礎設施的投資來加強生物銀行，尤其關注遺傳性疾病、近親結婚相關的疾病風險以及特定人群的健康洞察。

主要國家生物銀行的發展趨勢

中國正透過大規模基因組研究、醫院網路、癌症研究、感染疾病控制和精準醫療等舉措，不斷擴大生物銀行的規模，日益重視資料管治、檢體品質和標準化臨床註釋。美國是領先的生物銀行庫中心，擁有廣泛的學術和醫療網路、疾病特異性樣本庫、人群隊列、臨床試驗活動和先進的分子研究基礎設施，並專注於知情同意、隱私保護和機構監管。日本則將先進的臨床研究、老化相關隊列、腫瘤學、再生醫學以及高標準的檢體品質相結合。同時，印度的人口多樣性、感染疾病研究、非傳染性疾病研究以及不斷擴展的基因組醫學項目，都增強了其在生物銀行的重要性。德國強調品管、與病理學相結合的生物樣本庫、轉化研究和標準化流程，而英國擁有成熟的生物銀行生態系統，這得益於大規模隊列研究、綜合健康數據資源以及對研究數據獲取的嚴格管治。澳洲以其人口健康研究、癌症生物生物銀行、罕見疾病研究和健全的倫理框架而聞名，而法國則透過其臨床研究網路、癌症和罕見疾病項目以及系統的法律規範來支持生物銀行。韓國正透過其國家級生物樣本庫系統、基因組學、數位健康整合以及將生物檢體與臨床和分子資料集連接起來的精準醫療計畫來推動生物銀行。義大利和西班牙透過醫院生物樣本庫、腫瘤學研究、罕見疾病計畫和歐洲合作框架做出貢獻，而加拿大則透過人口健康研究、癌症和慢性病研究、對本土數據管治的考量以及旨在提高互通性和倫理獲取的國家努力來支持生物銀行。俄羅斯在人口遺傳學、感染疾病研究和生物醫學樣本庫方面保持著強大的實力，其數據管治和國際合作受到該國監管優先事項的影響。巴西和墨西哥是拉丁美洲的重要貢獻者，其發展動力來自癌症研究、感染疾病研究、代謝疾病負擔以及不斷擴大的基因組多樣性舉措。

為生物銀行領導者提供的實用建議

產業領導者應將生物檢體品質、資料互通性、倫理管治和營運韌性作為生物樣本庫策略的核心支柱。建立標準化的採集、處理、儲存和運輸流程對於減少分析前變異性、支持可重複性研究至關重要。各機構應投資於實驗室資訊管理系統、自動化庫存追蹤、溫度監控和可審計的儲存文檔，以增強可追溯性和合規性。為提升研究價值，生物樣本庫應在應用隱私保護存取檢體和尊重知情同意的資料管治的同時，利用結構化的臨床、基因組、影像和結果資料豐富其樣本。領導者還應採用國際認可的品管方法，為員工提供檢體科學的培訓，並定期評估冷凍庫、緊急電源、災害復原計畫和網路安全措施的效能。在國際合作中，統一的元元資料標準、通用資料模型、聯合搜尋工具和透明的存取政策有助於在不損害提供者權利的前提下促進檢體的利用。建立公眾信任同樣重要。清晰的知情同意說明、與當地社區的互動、在適當情況下返回檢測結果的政策以及公正的研究夥伴關係關係，有助於提高參與度並確保長期的合法性。最後，永續性計畫必須涵蓋節能儲存、設備生命週期管理以及基於風險的儲存政策，從而在科學價值與環境和營運責任之間取得平衡。

生物銀行分析的調查方法

穩健的生物銀行調查方法必須結合一級和二級調查、監管審查、專家檢驗以及證據的三角檢驗。一級資訊來源與生物樣本庫管理人員、檢查室管理員、臨床研究人員、倫理委員會成員、病理學家、資料管治專家、低溫運輸專家以及精準醫療相關人員的討論。二級調查應仔細審查同行評審文獻、公共衛生指南、臨床研究標準、生物樣本科學出版物、國家基因組計劃文件、資料保護條例和品管框架。為確保調查方法的嚴謹性，必須區分已證實的進展和宣傳性聲明，評估資訊來源的可重複性，並評估知情同意獲取、檢體轉移、隱私和認證實踐方面的區域差異。分析應概述生物樣本庫的工作流程，包括收集、處理、儲存、註釋、存取、分發和處置，並考慮檢體類型、疾病領域、最終用戶、技術應用和管治模式。研究結果應透過對多個資訊來源進行橫斷面比較檢驗，以確保科學論文、監管文件和專家意見之間的一致性。這種以證據為基礎的方法能夠客觀地了解生物銀行趨勢、營運重點、風險因素和策略機遇，而無需依賴推測性的規模估計或預測。

結論

生物銀行正逐漸發展成為精準醫療、轉化研究、公共衛生和疫情應變的關鍵基礎設施。其價值日益取決於生物檢體的品質、標準化的元資料、倫理許可、安全的資料共享以及支持多機構合作的能力。儘管區域生態系統的發展速度不盡相同，但通用的全球優先事項正在湧現：協調、自動化、隱私保護、永續性以及人工智慧的負責任使用。加強品管系統、互通性、社區信任和穩健的低溫運輸運營的國家和機構將更有利於加速生物標記的發現、改進患者分層並支持循證醫學創新。生物銀行的未來將由可靠、互聯且數據驅動的儲存庫塑造，這些儲存庫將生物檢體轉化為可操作的科學知識，同時保護捐贈者的權利和研究的完整性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：生物銀行市場：依產品/服務分類

  • 產品
    • 生物銀行設備
      • 自動化樣品儲存系統
      • 低溫儲存系統
      • 培養箱和離心機
      • 冷藏庫和冷凍庫
      • 檢體運送及包裝單元
    • 消耗品
  • 服務
    • 同意獲取和監管合規服務
    • 數據管理和生物資訊學
    • 檢體採集和處理服務
    • 檢體儲存服務
    • 檢體運輸及物流
  • 軟體

第8章：生物銀行市場：依生物樣本庫類型分類

  • 物理生物樣本庫
  • 虛擬生物樣本庫

第9章：生物銀行市場：依樣本類型分類

  • 血
    • 電漿
    • 血清
    • 全血
  • 細胞
  • DNA／RNA
  • 組織

第10章：生物銀行市場：依應用領域分類

  • 診斷和治療
  • 藥物發現與臨床研究

第11章：生物銀行市場：依最終使用者分類

  • 學術和研究機構
  • 受託研究機構（CRO）
  • 政府和公共衛生機構
  • 醫院和臨床檢查室
  • 製藥和生物技術公司

第12章：生物銀行市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章：生物銀行市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章：生物銀行市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • ASKION GmbH
  • Avantor, Inc.
  • Azenta Life Sciences, Inc.
  • BioKryo
  • BioLife Solutions, Inc.
  • Charles River Laboratories International, Inc.
  • Cryoport Systems, LLC
  • Cureline, Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • FIND
  • Firalis Molecular Precision
  • Greiner Bio-One International GmbH
  • Hamilton Company
  • Laboratory Corporation of America Holdings
  • LGC Biosearch Technologies
  • Merck KGaA
  • PerkinElmer, Inc.
  • PHC Corporation
  • Qiagen NV
  • Sampled
  • Sopachem BV
  • SPT Labtech Ltd
  • STEMCELL Technologies Inc.
  • Taylor-Wharton
  • Tecan Trading AG
  • Thermo Fisher Scientific Inc.
  • US Biolab Corporation, Inc.
  • VigiSolvo
Product Code: MRR-961BA04A2DC3

The Biobanking Market is projected to grow by USD 157.24 billion at a CAGR of 10.85% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 76.43 billion
Estimated Year [2026] USD 84.51 billion
Forecast Year [2032] USD 157.24 billion
CAGR (%) 10.85%

Biobanking Executive Summary

Biobanking has become foundational infrastructure for modern biomedical research, precision medicine, drug discovery, genomics, regenerative medicine, and public health preparedness. By collecting, processing, storing, annotating, and distributing biospecimens such as blood, tissue, DNA, RNA, cells, plasma, serum, and microbiome samples, biobanks enable researchers and clinicians to connect biological material with high-quality clinical, demographic, lifestyle, and molecular data. The sector is increasingly shaped by ethical consent models, interoperability standards, cold-chain reliability, automated storage systems, and secure data governance aligned with recognized biospecimen and laboratory quality practices. Demand is closely linked to the expansion of population genomics programs, oncology research, rare disease studies, longitudinal cohort research, infectious disease surveillance, and biomarker validation. As biobanking moves from sample storage toward integrated biospecimen intelligence, stakeholders are prioritizing specimen integrity, traceability, regulatory compliance, donor trust, and data quality. The strongest biobanking strategies now combine standardized pre-analytical workflows, digital inventory management, harmonized metadata, quality management systems, and privacy-preserving data access to support reproducible science and clinically relevant discoveries.

Transformative Shifts in the Biobanking Landscape

The biobanking landscape is undergoing a structural shift from repository-centered operations to data-rich, networked, and quality-driven platforms. Traditional freezer-based sample archives are being transformed through laboratory automation, robotic retrieval, cryogenic monitoring, barcode and RFID tracking, cloud-based laboratory information management systems, and standardized operating procedures designed to reduce variability in biospecimen handling. Regulatory and ethical expectations are also evolving, with greater attention to informed consent, dynamic consent, secondary use of specimens, data anonymization or pseudonymization, cross-border transfers, and equitable benefit sharing. Research programs increasingly require biospecimens linked to longitudinal clinical records, imaging, multi-omics datasets, treatment response, and real-world evidence, making metadata completeness as important as sample availability. Another major shift is the rise of decentralized and federated biobank networks, where institutions retain custody of specimens while enabling standardized discovery and controlled access across research ecosystems. Sustainability is also becoming central, as ultra-low-temperature storage and liquid nitrogen systems require robust energy management, backup planning, disaster recovery, and environmental accountability. These shifts are positioning biobanking as a strategic enabler of translational research rather than a passive support function.

Cumulative Impact of Artificial Intelligence on Biobanking

Artificial intelligence is reshaping biobanking by improving sample discovery, quality control, data harmonization, cohort identification, and operational efficiency. AI-enabled tools can support automated annotation of clinical and molecular datasets, identify inconsistencies in metadata, predict specimen degradation risks based on storage and handling variables, and optimize freezer utilization and retrieval workflows. In research settings, machine learning enhances the ability to link biospecimens with phenotypes, genotypes, imaging profiles, and treatment outcomes, accelerating biomarker discovery and patient stratification. Natural language processing can extract structured variables from clinical notes and pathology reports, improving the usability of historical biospecimen collections when appropriate governance is in place. AI also strengthens federated research models by enabling privacy-preserving analytics, where insights can be generated across distributed datasets without unnecessary movement of sensitive information. However, the cumulative impact of AI depends on data provenance, representative cohorts, transparent algorithms, auditability, cybersecurity, and compliance with privacy and research ethics requirements. Biobanks that invest in curated metadata, standardized vocabularies, consent-aware access controls, and AI governance will be better positioned to support reproducible, responsible, and high-value biomedical research.

Key Regional Insights Across Biobanking

Asia-Pacific is advancing rapidly as large population cohorts, genomic medicine initiatives, cancer research networks, and infectious disease preparedness programs increase the need for standardized biospecimen infrastructure across China, India, Japan, South Korea, Australia, and Southeast Asia. The region's population diversity offers strong scientific value for genomics, pharmacogenomics, and disease-risk studies, while also increasing the need for harmonized consent, sample export controls, data localization, and quality assurance. Europe has one of the most structured biobanking ecosystems, shaped by cross-border research collaboration, stringent data protection rules, established quality frameworks, and pan-European research infrastructures that support harmonization, responsible access, and specimen reuse. North America remains a highly developed biobanking environment, supported by mature academic medical centers, population health cohorts, clinical trial networks, advanced molecular diagnostics, and established human research protection frameworks. The United States and Canada place strong emphasis on institutional review, privacy compliance, interoperability, and biospecimen quality standards. Latin America is building biobanking capacity through cancer registries, infectious disease research, maternal and child health studies, and genomic diversity programs, with Brazil and Mexico playing important roles in regional research infrastructure development. Africa is gaining strategic importance due to its genetic diversity, infectious disease research needs, and expanding public health collaborations, although sustainable funding, cold-chain resilience, laboratory accreditation, and equitable governance remain critical priorities for long-term biobank development. The Middle East is investing in national genome programs, hereditary disease research, and healthcare modernization, with biobanking increasingly connected to precision medicine strategies, population-specific risk profiling, and rare disease research.

Key Group Insights Shaping Biobanking Priorities

NATO member countries are relevant to biobanking through health security, biodefense research, infectious disease preparedness, and resilient biomedical infrastructure, where secure data exchange, specimen traceability, and cross-institutional readiness support coordinated responses to emerging health threats. G7 countries generally demonstrate strong capabilities in academic research biobanks, clinical trial biospecimen management, national cohort studies, oncology biobanking, and standards-driven quality systems, making them influential in establishing best practices for ethical, interoperable, and reproducible biobanking. BRICS countries contribute significant biobanking relevance due to large and diverse populations, expanding biomedical research capabilities, public health priorities, and increasing adoption of genomics, although regulatory maturity, data governance, and infrastructure consistency vary across members. The European Union provides one of the most advanced governance environments for biobanking, where data protection, cross-border collaboration, research ethics, and infrastructure harmonization are central to biospecimen access and reuse. ASEAN biobanking activity is supported by growing clinical research capacity, infectious disease surveillance, cancer studies, and regional interest in genomic medicine, with harmonization needed across consent practices, biospecimen transport, laboratory quality, and data protection requirements. GCC countries are strengthening biobanking through national health transformation agendas, population genomics, rare disease research, and investments in precision medicine infrastructure, with particular focus on inherited disorders, consanguinity-associated disease risk, and population-specific health insights.

Key Country Insights in Biobanking

China is expanding biobanking through large-scale genomics, hospital networks, oncology research, infectious disease preparedness, and precision medicine initiatives, with increasing focus on data governance, sample quality, and standardized clinical annotation. The United States is a leading biobanking hub due to its extensive academic medical networks, disease-specific repositories, population cohorts, clinical trial activity, and advanced molecular research infrastructure, with strong emphasis on consent, privacy, and institutional oversight. Japan combines advanced clinical research, aging-related cohorts, oncology, regenerative medicine, and high standards for sample quality, while India's biobanking relevance is strengthened by population diversity, infectious disease research, noncommunicable disease studies, and growing genomic medicine programs. Germany emphasizes quality management, pathology-linked biobanks, translational research, and standardized processes, while the United Kingdom has a mature biobanking ecosystem supported by large cohort studies, integrated health data resources, and strong governance for research access. Australia is recognized for population health research, cancer biobanking, rare disease studies, and strong ethics frameworks, and France supports biobanking through clinical research networks, cancer and rare disease programs, and structured regulatory oversight. South Korea is advancing biobanking through national biorepository systems, genomics, digital health integration, and precision medicine programs that connect biospecimens with clinical and molecular datasets. Italy and Spain contribute through hospital-based biobanks, oncology research, rare disease programs, and European collaboration frameworks, while Canada supports biobanking through population health research, cancer and chronic disease studies, Indigenous data governance considerations, and national efforts to improve interoperability and ethical access. Russia maintains capabilities in population genetics, infectious disease research, and biomedical repositories, with data governance and international collaboration shaped by national regulatory priorities. Brazil and Mexico are important Latin American contributors, driven by cancer research, infectious disease studies, metabolic disease burdens, and growing genomic diversity initiatives.

Actionable Recommendations for Biobanking Leaders

Industry leaders should prioritize biospecimen quality, data interoperability, ethical governance, and operational resilience as core pillars of biobanking strategy. Establishing standardized collection, processing, storage, and shipment protocols is essential to reduce pre-analytical variability and support reproducible research. Organizations should invest in laboratory information management systems, automated inventory tracking, temperature monitoring, and audit-ready chain-of-custody documentation to strengthen traceability and compliance. To improve research value, biobanks should enrich specimens with structured clinical, genomic, imaging, and outcome data while applying privacy-preserving access controls and consent-aware data governance. Leaders should also adopt internationally recognized quality management practices, train personnel in biospecimen science, and regularly assess freezer performance, backup power, disaster recovery, and cybersecurity readiness. For global collaboration, harmonized metadata standards, common data models, federated discovery tools, and transparent access policies can improve specimen utilization without compromising donor rights. Building public trust is equally important; clear consent communication, community engagement, return-of-results policies where appropriate, and equitable research partnerships can improve participation and long-term legitimacy. Finally, sustainability programs should address energy-efficient storage, equipment lifecycle management, and risk-based retention policies to balance scientific value with environmental and operational responsibility.

Research Methodology for Biobanking Analysis

A robust biobanking research methodology should combine primary and secondary research, regulatory review, expert validation, and evidence triangulation. Primary inputs typically include discussions with biobank directors, laboratory managers, clinical researchers, ethics committee members, pathologists, data governance specialists, cold-chain experts, and precision medicine stakeholders. Secondary research should examine peer-reviewed literature, public health agency guidance, clinical research standards, biospecimen science publications, national genomics program documentation, data protection regulations, and quality management frameworks. Methodological rigor requires separating verified developments from promotional claims, assessing the reproducibility of sources, and evaluating regional differences in consent, sample transfer, privacy, and accreditation practices. The analysis should map biobanking workflows across collection, processing, storage, annotation, access, distribution, and disposal while considering biospecimen types, disease areas, end users, technology adoption, and governance models. Findings should be validated through cross-source comparison to ensure consistency across scientific publications, regulatory documents, and expert perspectives. This evidence-led approach supports an objective understanding of biobanking trends, operational priorities, risk factors, and strategic opportunities without relying on speculative sizing or forecasting.

Conclusion

Biobanking is evolving into a critical infrastructure layer for precision medicine, translational research, population health, and pandemic preparedness. Its value increasingly depends not only on stored specimens but also on biospecimen quality, standardized metadata, ethical consent, secure data linkage, and the ability to support multi-institutional research. Regional ecosystems are progressing at different speeds, yet common priorities are emerging worldwide: harmonization, automation, privacy protection, sustainability, and responsible use of artificial intelligence. Countries and institutions that strengthen quality systems, interoperability, community trust, and resilient cold-chain operations will be better positioned to accelerate biomarker discovery, improve patient stratification, and support evidence-based healthcare innovation. The future of biobanking will be defined by trusted, connected, and data-enabled repositories that transform biological samples into actionable scientific insight while protecting donor rights and research integrity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biobanking Market, by Offering

  • 7.1. Introduction
  • 7.2. Product
    • 7.2.1. Biobanking Equipment
      • 7.2.1.1. Automated Sample Storage Systems
      • 7.2.1.2. Cryogenic Storage Systems
      • 7.2.1.3. Incubators & Centrifuges
      • 7.2.1.4. Refrigerators & Freezers
      • 7.2.1.5. Sample Transport & Packaging Units
    • 7.2.2. Consumables
  • 7.3. Services
    • 7.3.1. Consent & Regulatory Compliance Services
    • 7.3.2. Data Management & Bioinformatics
    • 7.3.3. Sample Collection & Processing Services
    • 7.3.4. Sample Storage Services
    • 7.3.5. Sample Transport & Logistics
  • 7.4. Software

8. Biobanking Market, by Biobank Type

  • 8.1. Introduction
  • 8.2. Physical Biobanks
  • 8.3. Virtual Biobanks

9. Biobanking Market, by Sample Type

  • 9.1. Introduction
  • 9.2. Blood
    • 9.2.1. Plasma
    • 9.2.2. Serum
    • 9.2.3. Whole Blood
  • 9.3. Cells
  • 9.4. DNA/RNA
  • 9.5. Tissue

10. Biobanking Market, by Application

  • 10.1. Introduction
  • 10.2. Diagnostics & Therapeutics
  • 10.3. Drug Discovery & Clinical Research

11. Biobanking Market, by End User

  • 11.1. Introduction
  • 11.2. Academic & Research Institutions
  • 11.3. Contract Research Organizations (CROs)
  • 11.4. Government & Public Health Agencies
  • 11.5. Hospitals & Clinical Labs
  • 11.6. Pharmaceutical & Biotech Companies

12. Biobanking Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Biobanking Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Biobanking Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. ASKION GmbH
  • 16.2. Avantor, Inc.
  • 16.3. Azenta Life Sciences, Inc.
  • 16.4. BioKryo
  • 16.5. BioLife Solutions, Inc.
  • 16.6. Charles River Laboratories International, Inc.
  • 16.7. Cryoport Systems, LLC
  • 16.8. Cureline, Inc.
  • 16.9. Danaher Corporation
  • 16.10. Eurofins Scientific SE
  • 16.11. FIND
  • 16.12. Firalis Molecular Precision
  • 16.13. Greiner Bio-One International GmbH
  • 16.14. Hamilton Company
  • 16.15. Laboratory Corporation of America Holdings
  • 16.16. LGC Biosearch Technologies
  • 16.17. Merck KGaA
  • 16.18. PerkinElmer, Inc.
  • 16.19. PHC Corporation
  • 16.20. Qiagen N.V.
  • 16.21. Sampled
  • 16.22. Sopachem BV
  • 16.23. SPT Labtech Ltd
  • 16.24. STEMCELL Technologies Inc.
  • 16.25. Taylor-Wharton
  • 16.26. Tecan Trading AG
  • 16.27. Thermo Fisher Scientific Inc.
  • 16.28. US Biolab Corporation, Inc.
  • 16.29. VigiSolvo

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOBANKING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BIOBANKING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BIOBANKING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BIOBANKING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOBANKING MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOBANKING MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOBANKING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOBANKING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOBANKING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BIOBANKING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BIOBANKING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BIOBANKING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BIOBANKING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BIOBANKING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BIOBANKING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BIOBANKING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BIOBANKING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL BIOBANKING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL BIOBANKING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PRODUCT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRODUCT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOBANKING EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOBANKING EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOBANKING EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AUTOMATED SAMPLE STORAGE SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOMATED SAMPLE STORAGE SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AUTOMATED SAMPLE STORAGE SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CRYOGENIC STORAGE SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CRYOGENIC STORAGE SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CRYOGENIC STORAGE SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INCUBATORS & CENTRIFUGES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INCUBATORS & CENTRIFUGES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INCUBATORS & CENTRIFUGES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL REFRIGERATORS & FREEZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL REFRIGERATORS & FREEZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL REFRIGERATORS & FREEZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SAMPLE TRANSPORT & PACKAGING UNITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SAMPLE TRANSPORT & PACKAGING UNITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SAMPLE TRANSPORT & PACKAGING UNITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONSENT & REGULATORY COMPLIANCE SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CONSENT & REGULATORY COMPLIANCE SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONSENT & REGULATORY COMPLIANCE SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DATA MANAGEMENT & BIOINFORMATICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DATA MANAGEMENT & BIOINFORMATICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DATA MANAGEMENT & BIOINFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SAMPLE COLLECTION & PROCESSING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SAMPLE COLLECTION & PROCESSING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SAMPLE COLLECTION & PROCESSING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SAMPLE STORAGE SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SAMPLE STORAGE SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SAMPLE STORAGE SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SAMPLE TRANSPORT & LOGISTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SAMPLE TRANSPORT & LOGISTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SAMPLE TRANSPORT & LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PHYSICAL BIOBANKS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHYSICAL BIOBANKS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PHYSICAL BIOBANKS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VIRTUAL BIOBANKS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VIRTUAL BIOBANKS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VIRTUAL BIOBANKS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL WHOLE BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL WHOLE BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL WHOLE BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DNA/RNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DNA/RNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DNA/RNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DRUG DISCOVERY & CLINICAL RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG DISCOVERY & CLINICAL RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DRUG DISCOVERY & CLINICAL RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CONTRACT RESEARCH ORGANIZATIONS (CROS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CONTRACT RESEARCH ORGANIZATIONS (CROS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CONTRACT RESEARCH ORGANIZATIONS (CROS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GOVERNMENT & PUBLIC HEALTH AGENCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GOVERNMENT & PUBLIC HEALTH AGENCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GOVERNMENT & PUBLIC HEALTH AGENCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOSPITALS & CLINICAL LABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HOSPITALS & CLINICAL LABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HOSPITALS & CLINICAL LABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PHARMACEUTICAL & BIOTECH COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PHARMACEUTICAL & BIOTECH COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PHARMACEUTICAL & BIOTECH COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOBANKING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BIOBANKING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BIOBANKING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BIOBANKING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA BIOBANKING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST BIOBANKING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL BIOBANKING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. NATO BIOBANKING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. NATO BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 165. NATO BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 166. NATO BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 167. NATO BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 168. NATO BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. NATO BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. NATO BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 171. NATO BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. NATO BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. G7 BIOBANKING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. G7 BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 175. G7 BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 176. G7 BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 177. G7 BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 178. G7 BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 181. G7 BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. G7 BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS BIOBANKING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION BIOBANKING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN BIOBANKING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. GCC BIOBANKING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. GCC BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 215. GCC BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 216. GCC BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 217. GCC BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. GCC BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. GCC BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. GCC BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 221. GCC BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. GCC BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL BIOBANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. JAPAN BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. JAPAN BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 246. JAPAN BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 247. JAPAN BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 248. JAPAN BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 249. JAPAN BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. JAPAN BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. JAPAN BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 252. JAPAN BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. JAPAN BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. INDIA BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. INDIA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 256. INDIA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 257. INDIA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 258. INDIA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 259. INDIA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. INDIA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. INDIA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 262. INDIA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. INDIA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 269. GERMANY BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. GERMANY BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. GERMANY BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 272. GERMANY BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. GERMANY BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED KINGDOM BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED KINGDOM BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED KINGDOM BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. AUSTRALIA BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. AUSTRALIA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 286. AUSTRALIA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 287. AUSTRALIA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 288. AUSTRALIA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 289. AUSTRALIA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. AUSTRALIA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. AUSTRALIA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 292. AUSTRALIA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. AUSTRALIA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. FRANCE BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. FRANCE BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 296. FRANCE BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. FRANCE BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 302. FRANCE BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 303. FRANCE BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. SOUTH KOREA BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. SOUTH KOREA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 306. SOUTH KOREA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 307. SOUTH KOREA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 308. SOUTH KOREA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 309. SOUTH KOREA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. SOUTH KOREA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. SOUTH KOREA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 312. SOUTH KOREA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 313. SOUTH KOREA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. ITALY BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. ITALY BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 316. ITALY BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 317. ITALY BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 318. ITALY BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 319. ITALY BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. ITALY BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. ITALY BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 322. ITALY BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 323. ITALY BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 324. CANADA BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 325. CANADA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 326. CANADA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 327. CANADA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 328. CANADA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 329. CANADA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. CANADA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. CANADA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 332. CANADA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 333. CANADA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 334. RUSSIA BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 335. RUSSIA BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 336. RUSSIA BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 337. RUSSIA BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 338. RUSSIA BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 339. RUSSIA BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. RUSSIA BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. RUSSIA BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 342. RUSSIA BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 343. RUSSIA BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 344. BRAZIL BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 345. BRAZIL BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 346. BRAZIL BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 347. BRAZIL BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 348. BRAZIL BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 349. BRAZIL BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 350. BRAZIL BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 351. BRAZIL BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 352. BRAZIL BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 353. BRAZIL BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 354. MEXICO BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 355. MEXICO BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 356. MEXICO BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 357. MEXICO BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 358. MEXICO BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 359. MEXICO BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 360. MEXICO BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 361. MEXICO BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 362. MEXICO BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 363. MEXICO BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 364. SPAIN BIOBANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 365. SPAIN BIOBANKING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 366. SPAIN BIOBANKING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 367. SPAIN BIOBANKING MARKET SIZE, BY BIOBANKING EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 368. SPAIN BIOBANKING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 369. SPAIN BIOBANKING MARKET SIZE, BY BIOBANK TYPE, 2018-2032 (USD MILLION)
  • TABLE 370. SPAIN BIOBANKING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 371. SPAIN BIOBANKING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 372. SPAIN BIOBANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 373. SPAIN BIOBANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 374. GLOBAL BIOBANKING MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 375. GLOBAL BIOBANKING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025